US 12,227,588 B2
Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor T cells against T cell lymphomas and leukemias
Marco Ruella, Ardmore, PA (US); Saar Gill, Philadelphia, PA (US); Carl H. June, Merion Station, PA (US); Avery D. Posey, Philadelphia, PA (US); and Daniel J. Powell, Bala Cynwyd, PA (US)
Assigned to The Trustees of the University of Pennsylvania, Philadelphia, PA (US)
Filed by THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, Philadelphia, PA (US)
Filed on Mar. 28, 2024, as Appl. No. 18/620,748.
Application 18/620,748 is a continuation of application No. 18/304,843, filed on Apr. 21, 2023.
Application 18/304,843 is a continuation of application No. 17/416,365, granted, now 11,673,964, issued on Jun. 13, 2023, previously published as PCT/US2019/067613, filed on Dec. 19, 2019.
Claims priority of provisional application 62/782,131, filed on Dec. 19, 2018.
Prior Publication US 2024/0228655 A1, Jul. 11, 2024
Int. Cl. C07K 16/28 (2006.01); A61K 35/17 (2015.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); C07K 14/47 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C12N 5/0783 (2010.01)
CPC C07K 16/2896 (2013.01) [A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464429 (2023.05); A61P 35/00 (2018.01); A61P 35/02 (2018.01); C07K 14/70507 (2013.01); C07K 14/7051 (2013.01); C07K 14/70578 (2013.01); C07K 14/70596 (2013.01); C07K 16/2803 (2013.01); C07K 16/2806 (2013.01); C12N 5/0636 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); C07K 14/4748 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01)] 22 Claims
 
1. A chimeric antigen receptor comprising an antigen binding domain comprising a heavy chain variable region comprising the HCDR1, HCDR2, and HCDR3 of SEQ ID NO: 75, and a light chain variable region comprising the LCDR1, LCDR2, and LCDR3 of SEQ ID NO: 76.